ImmunityBio shares gained after Macau approved its drug Anktiva for bladder cancer, its first Asian authorization, supporting global expansion amid a growing immunotherapy market.Read More
ImmunityBio Stock Rises on Macau Approval for Anktiva Bladder Cancer Drug
